Waystar Holding Corp. Signals Confident, Profitable Growth

Waystar Holding Corp. ((WAY)) has held its Q4 earnings call. Read on for the main highlights of the call.

Waystar Holding Corp.’s latest earnings call struck an upbeat tone, underscored by record bookings, double‑digit revenue growth and robust margins. Management balanced this optimism with a sober view of risks around seasonality, acquisition‑related cost step‑ups and the timing lag between large bookings and revenue, but the overall message was one of confident, disciplined growth.

Record Annual Revenue and Confident 2026 Outlook

Waystar closed fiscal 2025 with $1.1 billion in revenue, up 17% year over year, including 13% organic growth, signaling strong demand for its healthcare payments platform. For 2026, the company is guiding to $1.274 billion to $1.294 billion in revenue, implying about 17% growth and roughly 10% normalized organic expansion at the midpoint.

Q4 Top-Line Strength Across Revenue Streams

Fourth‑quarter 2025 revenue reached $304 million, jumping 24% from a year earlier with 12% organic growth, as both subscription and volume‑based revenue pulled their weight. The mix shows Waystar benefiting not only from long‑term contracts but also from growing transaction volumes across its customer base.

Margin Expansion Underpins Profitability Story

Adjusted EBITDA in Q4 climbed to $129 million, up 29% year over year, delivering a roughly 43% margin that highlights solid operating leverage. For the full year, adjusted EBITDA of $462 million and a 42% margin, alongside 2026 guidance midpoint of $535 million at about a 42% margin, point to durable profitability even as the business invests for growth.

Record Bookings and Large-Deal Momentum

Management highlighted a record bookings quarter driven by an elevated number of $1 million‑plus deals, with 15 to 20 such wins in both Q3 and Q4, more than double the three‑year quarterly average. These large contracts enhance revenue visibility, though many are expected to ramp over six to eighteen months, creating some timing risk between bookings and recognized revenue.

Iodine Acquisition Expands Scale and Synergies

The Iodine acquisition added $31 million in Q4 revenue and more than 1,000 hospitals and health systems, with about 35% customer overlap that should support cross‑selling. Waystar is ahead of plan on integration and expects to realize over 90% of its committed $15 million in cost synergies in fiscal 2026, or roughly $14 million, providing about a one‑point margin uplift.

AI Engine Driving Measurable Client Outcomes

Waystar’s Altitude AI platform prevented more than $15 billion in denials in 2025, cut appeal package generation time by 90% and delivered double‑digit improvements in denial overturn rates, demonstrating tangible value for providers. Around 50 solutions now leverage AI, accounting for about 40% of revenue, and roughly 30% of 2025 new bookings were AI‑powered, underscoring AI as a core growth driver.

Customer Retention and Satisfaction Remain Standout Strengths

Net revenue retention over the last twelve months reached 112% with 97% gross revenue retention, while the net promoter score topped 70, reflecting strong customer loyalty and expansion. The number of clients generating more than $100,000 in trailing twelve‑month revenue rose by 85 in Q4 to 1,391, up 16% year over year, as win rates improved beyond the historical ~80% level.

Cash Generation Supports Deleveraging Agenda

Unlevered free cash flow was $80 million in Q4 and $365 million for the year, converting roughly 79% of adjusted EBITDA into cash and highlighting high cash efficiency. Net leverage stood at about 3.0x at year‑end, down roughly half a turn since the Iodine close, and management reiterated plans to run at or below 3.0x and delever by around one turn annually.

Seasonality Weighs on Patient Payment Growth

Volume‑based revenue reached $134 million in Q4, growing 11% year over year but just 1% sequentially, as patient payment solutions softened versus Q3 due to deductible seasonality and high‑deductible plan dynamics. This pattern feeds into 2026 guidance, where management flagged Q3 as likely to be at the low end of sequential growth due to typical patient‑payment softness.

Higher Operating Costs from Iodine Integration

Operating expenses in G&A, R&D and depreciation and amortization stepped up in Q4 as the company absorbed a full quarter of Iodine, temporarily muting margin expansion. The acquisition contributed only about $2 million of adjusted EBITDA synergy in Q4, or around a one‑point margin uplift, with the bulk of the expected $14 million synergy benefit slated for 2026.

Leverage and Cash Balance Remain Key Watchpoints

Waystar ended the quarter with $86 million in cash and equivalents against $1.5 billion of gross debt, leaving net leverage around 3.0x. While management is actively deleveraging and targeting a lower leverage profile over time, the current debt load still represents an overhang that investors will be monitoring closely.

One-Off Tailwinds Boosting Retention Metrics

Management acknowledged that part of the elevated time‑to‑revenue and net revenue retention performance stemmed from clients affected by a competitor’s 2024 cyber incident. This disclosure suggests some recent retention and expansion benefits may be non‑recurring, warranting caution when extrapolating current NRR levels into the long term.

Lag Between Large Deals and Revenue Recognition

The surge in large bookings, while positive for long‑term growth, comes with a six‑ to eighteen‑month implementation and ramp period before revenue fully materializes. This lag introduces quarterly variability as the company balances near‑term reported growth with the build‑up of a sizable contracted backlog that should support results beyond 2026.

Reliance on Healthcare Utilization Trends

Waystar’s outlook assumes “healthy” patient utilization levels, which underpin its roughly 10% normalized organic growth target and a similar trajectory for Iodine. Any downturn in healthcare utilization could pressure both volume‑based and consumption‑linked subscription revenue, making macro and utilization trends an important external swing factor.

Guidance Points to Sustained, Profitable Growth

For 2026, Waystar is guiding revenue to $1.274 billion to $1.294 billion, implying about 17% year‑over‑year growth with roughly 10% normalized organic expansion and modest sequential increases of 1% to 3% through the year. Adjusted EBITDA is projected at $530 million to $540 million with a margin near 42%, supported by roughly $14 million of acquisition synergies, while management plans to keep net leverage at or below ~3.0x and continue annual deleveraging.

Waystar’s earnings call painted a picture of a company executing well on growth, profitability and AI‑driven innovation, while carefully managing integration and leverage risks. For investors, the combination of strong bookings, high retention, robust cash flow and disciplined guidance suggests a solid foundation, though healthcare utilization trends and the timing of large‑deal ramps will remain critical variables to watch.